Proliferation-Linked Apoptosis of Adoptively Transferred T Cells after IL-15 Administration in Macaques

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Berger, Carolina ^a,b   Berger, Michael ^a   Beard, Brian C ^a,b   Kiem, Hans Peter ^a,b   Gooley, Theodore A ^a   Riddell, Stanley R ^a,b,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 15;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD; BONE MARROW; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CYCLE; CELL DEATH; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG SAFETY; EFFECTOR CELL; HEMOSTASIS; IMMUNOLOGICAL MEMORY; IN VIVO STUDY; LOW DRUG DOSE; LYMPH NODE; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; MACACA NEMESTRINA; NONHUMAN; PHENOTYPE; REGULATORY T LYMPHOCYTE; REPEATED DRUG DOSE;

ADOPTIVE TRANSFER; ANIMALS; APOPTOSIS; BONE MARROW; CD8-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CELL PROLIFERATION; CLONE CELLS; CYTOMEGALOVIRUS; IMMUNOLOGIC MEMORY; INTERLEUKIN-15; LYMPH NODES; MACACA NEMESTRINA; TIME FACTORS;

EID: 84873920630     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056268     Document Type: Article

References (48)

1. Riddell SR, Watanabe KS, Goodrich JM, Li C-R, Agha ME, et al. (1992) Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257: 238-241.
2. Blattman JN, Greenberg PD, (2004) Cancer immunotherapy: a treatment for the masses. Science 305: 200-205.
3. Riddell SR, (2004) Finding a place for tumor-specific T cells in targeted cancer therapy. J Exp Med 200: 1533-1537.
4. June CH, (2007) Adoptive T cell therapy for cancer in the clinic. J Clin Invest 117: 1466-1476.
5. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME, (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8: 299-308.
6. Brenner MK, Heslop HE, (2010) Adoptive T cell therapy of cancer. Curr Opin Immunol 22: 251-257.
7. Berger C, Turtle CJ, Jensen MC, Riddell SR, (2009) Adoptive transfer of virus-specific and tumor-specific T cell immunity. Curr Opin Immunol 21: 224-232.
8. Restifo NP, Dudley ME, Rosenberg SA, (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12: 269-281.
9. Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF, et al. (2004) Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 173: 7125-7130.
10. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, et al. (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17: 4550-4557.
11. Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC, et al. (2001) Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 24: 363-373.
12. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, et al. (2002) Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred cells. Proc Natl Acad Sci USA 99: 16168-16173.
13. Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, et al. (2008) Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 118: 294-305.
14. Wang X, Berger C, Wong CW, Forman SJ, Riddell SR, et al. (2011) Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice. Blood 117: 1888-1898.
15. Chapuis AG, Casper C, Kuntz S, Zhu J, Tjernlund A, et al. (2011) HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo. Blood 117: 5391-5402.
16. Chapuis AG, Thompson JA, Margolin KA, Rodmyre R, Lai IP, et al. (2012) Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc Natl Acad Sci USA 109: 4592-4597.
17. Powell Jr DJ, Dudley ME, Robbins PF, Rosenberg SA, (2005) Transition of late stage effector T cells to CD27+CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 105: 241-250.
18. Wang A, Chandran S, Shah SA, Chiu Y, Paria BC, et al. (2012) The stoichiometric production of IL-2 and IFN-γ mRNA defines memory T cells that can self-renew after adoptive transfer to humans. Sci Transl Med 4: 149ra120.
19. Grabstein KH, Eisenman J, Shanebeck K, Rauch C, Srinivasan S, et al. (1994) Cloning of a T cell growth factor that interacts with the β chain of the interleukin-2 receptor. Science 264: 965-968.
20. Ku CC, Murakami M, Sakamoto A, Kappler J, Marrack P, (2000) Control of homeostasis of CD8+ memory T cells by opposing cytokines. Science 288: 675-678.
21. Purton JF, Tan JT, Rubinstein MP, Kim DM, Sprent J, et al. (2007) Antiviral CD4+ memory T cells are IL-15 dependent. J Exp Med 204: 951-961.
22. Sato N, Patel HJ, Waldmann TA, Tagaya Y, (2007) The IL-15/IL15Rα on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells. Proc Natl Acad Sci USA 104: 588-593.
23. Waldmann TA, (2006) The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 6: 595-601.
24. Ring AM, Lin JX, Feng D, Mitra S, Rickert M, et al. (2012) Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15. Nat Immunol 13: 1187-1195.
25. Berger C, Berger M, Hackman RC, Gough M, Jensen MC, et al. (2009) Safety and immunological effects of IL-15 administration in nonhuman primates. Blood 114: 2417-2426.
26. Eisenman J, Ahdieh M, Beers C, Brasel K, Kennedy MK, et al. (2002) Interleukin-15 interactions with interleukin-15 receptor complexes: characterization and species specificity. Cytokine 20: 121-129.
27. Berger C, Berger M, Anderson DE, Riddell SR, (2011) A non-human primate model for analysis of safety, persistence, and function of adoptively transferred T cells. J Med Primatol 40: 88-103.
28. Sallusto F, Lenig D, Foerster R, Lipp M, Lanzavecchia A, (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401: 708-712.
29. Unsoeld H, Pircher H, (2005) Complex memory T-cell phenotypes revealed by coexpression of CD62L and CCR7. J Virol 79: 4510-4513.
30. Yang S, Liu F, Wang QJ, Rosenberg SA, Morgan RA, (2011) The shedding of CD62L (L-Selectin) regulates the acquisition of lytic activity in human tumor reactive T lymphocytes. PLoS ONE 6: e22560.
31. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, et al. (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333: 1038-1044.
32. Riddell SR, Elliott M, Lewinsohn DA, Gilbert MJ, Wilson L, et al. (1996) T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 2: 216-223.
33. Berger C, Huang M-L, Gough M, Greenberg PD, Riddell SR, et al. (2001) Nonmyeloablative immunosuppressive regimen prolongs in vivo persistence of gene-modified autologous T cells in a nonhuman primate model. J Virol 75: 799-808.
34. Picker LJ, Reed-Inderbitzin EF, Hagen SI, Edgar JB, Hansen SG, et al. (2006) IL-15 induces CD4+ effector memory T cell production and tissue emigration in nonhuman primates. J Clin Invest 116: 1514-1524.
35. Lugli E, Goldman CK, Perera LP, Smedley J, Pung R, et al. (2010) Transient and persistent effects of IL15 on lymphocyte homeostasis in nonhuman primates. Blood 116: 3238-3248.
36. Baerlocher GM, Lansdorp PM, (2003) Telomere length measurements in leukocyte subsets by automated multicolor flow-FISH. Cytometry A 55A: 1-6.
37. Adair JE, Beard BC, Trobridge GD, Neff T, Rockhill JK, et al. (2012) Extended survival of glioblastoma patients after chemoprotective HSC gene therapy. Sci Transl Med 4: 133ra57.
38. Beard BC, Dickerson D, Beebe K, Gooch C, Fletcher J, et al. (2007) Comparison of HIV-derived lentiviral and MLV-based gammaretroviral vector integration sites in primate repopulating cells. Mol Ther 15: 1356-1365.
39. Wei X, Sipkins DA, Pitsillides CM, Novak J, Georgakoudi I, et al. (2005) Real-time detection of circulating apoptotic cells by in vivo flow cytometry. Mol Imaging 4: 415-416.
40. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C, (1995) A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 184: 39-51.
41. Gattinoni L, Zhong X-S, Palmer DC, Ji Y, Hinrichs CS, et al. (2009) Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med 15: 808-813.
42. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, et al. (2011) A human memory T cell subset with stem cell-like properties. Nat Med 17: 1290-1297.
43. Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, et al. (2004) IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci USA 101: 1969-1974.
44. Roychowdhury S, May Jr KF, Tzou KS, Lin T, Bhatt D, et al. (2004) Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not with low-dose interleukin 2. Cancer Res 64: 8062-8067.
45. Teague RM, Sather BD, Sacks JA, Huang MZ, Dossett ML, et al. (2006) Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat Med 12: 335-341.
46. Markley JC, Sadelain M, (2010) IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T-cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood 115: 3508-3519.
47. Klebanoff CA, Gattinoni L, Palmer DC, Muranski P, Ji Y, et al. (2011) Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin Cancer Res 17: 5343-5352.
48. Nolz JC, Rai D, Badovinac VP, Harty JT, (2012) Division-linked generation of death-intermediates regulates the numerical stability of memory CD8 T cells. Proc Natl Acad Sci USA 109: 6199-6204.